Synthetic cannabinoids trigger psychiatric crises through hidden brain chemistry

This study investigated why certain synthetic cannabinoid receptor agonists (SCRAs)—illicit compounds designed to mimic cannabis effects—produce unexpected and severe psychiatric symptoms. Researchers discovered that many SCRAs with specific chemical structures (valinamide and tert-leucinamide types) interact not only with cannabinoid receptors but also directly activate 5-HT2A receptors, which are involved in serotonin signaling and hallucinations. The most potent compound tested, AB-5'F-BUTINACA, showed significant activity at both receptor types, suggesting a dual mechanism of action not previously understood.

In animal studies, AB-5'F-BUTINACA produced a range of neurological effects including altered sensory perception, pain suppression, body temperature changes, and reduced movement. Crucially, researchers demonstrated that blocking either the CB1 receptor or the 5-HT2A receptor separately prevented many of these effects, confirming both receptors contribute to the compound's harmful outcomes. This represents the first evidence that SCRAs can directly activate serotonin receptors, explaining why users report psychiatric crises, hallucinations, and severe anxiety—effects that go beyond what traditional cannabis produces.

The implications are significant for public health: illicit SCRAs pose greater risks than natural cannabis due to their dual activation of cannabinoid and serotonin pathways, which can independently trigger psychiatric symptoms. This finding helps explain why synthetic cannabinoids are associated with more severe adverse events, including psychosis and suicidal ideation, compared to regular cannabis use. Understanding this mechanism is essential for emergency responders, mental health professionals, and policymakers addressing the synthetic cannabinoid crisis.